the future of glp 1 drugs What is pipeline for medications for obesity? GLP-1 Market Trends and Global

At PEAK, every patient receives a full clinical program not just a prescription

By binding to the GLP-1R, GLP-1 is able to exercise its effects on a wide variety of cells and tissues

Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ

89 specifically in obese patients with T2D who were treated with varying doses of Liraglutide

[DOI] [PubMed] [Google Scholar] 93.Salvo F., Moore N., Arnaud M., Robinson P., Raschi E., De Ponti F., Bgaud B., Pariente A

2013;304(2):F137F144